Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Eupraxia Pharmaceuticals’ promising EP-104IAR treatment for knee osteoarthritis has gained attention following its publication in the prestigious Lancet Rheumatology journal. The Phase 2b trial results highlight its potential to offer significant pain relief with a favorable safety profile. This development could mark a significant advancement in the treatment of knee osteoarthritis, affecting over 30 million people in the U.S.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
